Our findings demonstrate that inhibition of DHODH can suppress metastatic progression of a CRC cell line that is resistant to 5-FU—revealing promise for clinical testing of this agent in patients at high risk for relapse and whose tumors may exhibit resistance to 5-FU. This evidence concerns the gene DHODH and colorectal carcinoma.